Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $3.7 million.

  • Fennec Pharmaceuticals' Accumulated Expenses rose 1171.14% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 1171.14%. This contributed to the annual value of $3.4 million for FY2024, which is 868.41% down from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Accumulated Expenses stood at $3.7 million, which was up 1171.14% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Accumulated Expenses peaked at $4.4 million during Q1 2024, and registered a low of $171000.0 during Q2 2021.
  • Over the past 5 years, Fennec Pharmaceuticals' median Accumulated Expenses value was $1.6 million (recorded in 2022), while the average stood at $1.9 million.
  • The largest annual percentage gain for Fennec Pharmaceuticals' Accumulated Expenses in the last 5 years was 32786.07% (2021), contrasted with its biggest fall of 6068.97% (2021).
  • Over the past 5 years, Fennec Pharmaceuticals' Accumulated Expenses (Quarter) stood at $860000.0 in 2021, then soared by 158.02% to $2.2 million in 2022, then surged by 69.18% to $3.8 million in 2023, then decreased by 8.68% to $3.4 million in 2024, then increased by 7.96% to $3.7 million in 2025.
  • Its Accumulated Expenses stands at $3.7 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.8 million for Q1 2025.